Search hospitals
>
Illinois
>
Urbana
Carle Cancer Center
Claim this profile
Urbana, Illinois 61801
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Pancreatic Cancer
Conducts research for Breast cancer
793 reported clinical trials
16 medical researchers
Summary
Carle Cancer Center is a medical facility located in Urbana, Illinois. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Pancreatic Cancer, Breast cancer and other specialties. Carle Cancer Center is involved with conducting 793 clinical trials across 605 conditions. There are 16 research doctors associated with this hospital, such as Suparna Mantha, Vamsi K. Vasireddy, Maria T. Grosse-Perdekamp, and Kendrith Rowland, MD.
Area of expertise
Breast Cancer
Carle Cancer Center has run 167 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Carle Cancer Center has run 114 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Suparna Mantha
Carle Cancer Center
6 years of reported clinical research
Vamsi K. Vasireddy
Carle Cancer Center
3 years of reported clinical research
Maria T. Grosse-Perdekamp
Carle Cancer Center
3 years of reported clinical research
Kendrith Rowland, MD
Carle Cancer Center
8 years of reported clinical research
Clinical Trials running at Carle Cancer Center
Lung Cancer
Breast Cancer
Prostate Cancer
Breast cancer
Cancer
Pancreatic Cancer
Multiple Myeloma
Kidney Cancer
Ovarian Cancer
Esophageal cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting
2 awards
Phase 3
4 criteria
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting
2 awards
Phase 3
12 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Carle Cancer Center?
Carle Cancer Center is a medical facility located in Urbana, Illinois. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Pancreatic Cancer, Breast cancer and other specialties. Carle Cancer Center is involved with conducting 793 clinical trials across 605 conditions. There are 16 research doctors associated with this hospital, such as Suparna Mantha, Vamsi K. Vasireddy, Maria T. Grosse-Perdekamp, and Kendrith Rowland, MD.
Where is Carle Cancer Center located?
**Carle Cancer Institute, Urbana, IL** - **Address:** 509 W. University Ave, Urbana, IL - **Phone:** (217) 383-3010 - **Facility Type:** Outpatient - **Additional Information:** For parking and further details, please visit the official Carle website.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance-related inquiries at Carle Cancer Center, contact Carle Patient Financial Services at (888) 71-CARLE, (888) 712-2753, available Monday through Friday, 8 a.m. to 5 p.m. Translated copies of Carle Financial Assistance Program materials are available in Spanish at Carle.org/FinancialAssistance or by request at FinancialAssistance@Carle.com. To apply for financial assistance, download the application from the Carle Health website or contact them for assistance.
What insurance does Carle Cancer Center accept?
The Carle Cancer Center accepts a range of insurance plans, including Carle Health, Medicare, Aetna, Blue Cross Blue Shield, Cigna, Humana, and UnitedHealthcare. Coverage may vary by location and service type. Patients should verify their plan's coverage for in-network or out-of-network benefits.
What awards or recognition has Carle Cancer Center received?
Carle Cancer Center in Urbana, Illinois, is supported by the Cancer Center at Illinois 2022 grants, enhancing cancer research collaborations on the University of Illinois Urbana-Champaign campus. It is also recognized for its research efforts through the Stephens Family Clinical Research Institute, focusing on new discoveries and best practices in healthcare.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.